SmartTRAK spoke with the Westbrook Weaver, CEO of Tempo Therapeutics, to discuss the company’s new technology, how it works and the results of the clinical work they’ve completed so far.

In the wound care space, there has always been an unmet need for a product that can provide volumetric wound filling in addition to simply closing the wound. Tempo Therapeutics is looking to utilize microporous annealed particle technology, or MAP, to address this need. In an interview with SmartTRAK, Westbrook Weaver, PhD, President and CEO of Tempo Therapeutics introduces their technology for creating a three-dimensional scaffold.

To learn more about Tempo Therapeutics, click on the following video (16:41 min). A link to download a complete transcript of the interview is also provided below.

Interview Transcript:
 

The North American Neuromodulation Society (NANS) is once again bringing together the leading clinicians, researchers and manufacturers to Caesar’s Palace in Las Vegas for the NANS 2026 Annual Meeting, to be held January 22-25.

SmartTRAK will be represented at NANS 2026 by Anne Staylor, SmartTRAK’s Executive Editor and VP & GM, Neuro Therapies, and Thom Clark, Sr Director, Enterprise Strategy & Solutions. If you would like to meet with us, please reach out to anne.staylor@smarttrak.com, or just click the button below.

To get you up to speed before the meeting, SmartTRAK has put together highlights of recent neuromodulation news. The following is just a small sampling of recent neuromodulation-related news and updates from around the world compiled, reviewed and posted in real-time every day by the expert analysts at SmartTRAK.

Market

• SmartTRAK estimates full-year US DBS Market revenues for 2025 will be up approximately +11% YoY, which is in line w/ SmartTRAK’s US DBS Market Overview projection of +10.8% YoY growth. SmartTRAK Financial Dashboard
• Based on SCS revenue YTD 2025, the US SCS Market is growing +2.9% YoY, which is in line w/ SmartTRAK’s original SCS Market Overview projection of +3.0% YoY growth. SmartTRAK Financial Dashboard
• Payer scrutiny and preauths will continue to place downward pressure on SCS, particularly because of CMS’ WISeR model set to launch 1/1/26. WISeR is piloting the preauth of SCS perm implants (NCD 160.7) for standard Medicare pts in 6 states. SmartTRAK Q325 Neuromodulation Recap
• GMED sees an opportunity to grow the NVRO business through surgeon conversion and competitive rep recruitment and views SCS as a continuum of spine care rather than as a standalone therapy. SmartTRAK Q325 Neuromodulation Market Recap
• A large unmet need exists in epilepsy, as one-third of patients (36%) do not benefit from drugs. This results in a global DRE prevalence of approximately 10MM people, w/ 1MM in the US, 2MM in Europe and 7MM in the ROW. LIVN 2025 Investor Day Presentation 
• Bioventus believes the acquisition of Nalu by BSX validates the potential of the PNS mkt. In the US, the PNS mkt is ~$200MM and is estimated to grow above 20% annually, exceeding $500MM by 2029. Bioventus Q325 Earnings Presentation  

Clinical/Regulatory/New Products

• NPCE announced it filed a FDA PMA-S application to expand the RNS System’s labeled indication to include pts w/ medication-resistant idiopathic generalized epilepsy w/ generalized tonic-clonic seizures. The PMA-S was supported by preliminary results of the NAUTILUS trial.
• The FDA approved BSX’ PMA supplement for the WaveWriter SCS MRI Safety Guidelines to add the MDT Specify SureScan MRI Leads to the list of compatible w/ the BSX M8 Adaptor and to label WaveWriter Alpha SCS Mixed System using MDT’s Specify SureScan leads as MRI scan eligible.

Chance Leonard and R. Sean Churchill, MD, MBA, of Genesis Innovation Group and Capitan Orthopedics, discuss their SupraSpacer implant for treatment of massive irreparable rotator cuff tears in an interview with SmartTRAK. 

In an interview with SmartTRAK, Chance Leonard and R. Sean Churchill, MD, MBA, of Genesis Innovation Group and Capitan Orthopedics, discuss the innovative SupraSpacer implant for the treatment of massive irreparable rotator cuff tears and how it can provide a minimally invasive procedure that delivers stable, pain-free range of motion and helps preserve future surgical options.

To find out more about Capitan Orthopedics and the SupraSpacer implant, click on the following video (37:07 min). A link to download a complete transcript of the interview is provided below. 

Interview Transcript:

Hey everybody. It's Andy Knapik here from SmartTRAK. I am senior analyst for soft tissue fixation and arthroscopic technologies. And today I'm really excited to be joined by a couple of gentlemen who are designing what I think is a pretty unique and very much needed product right now in the rotator cuff space. So I'm joined by Chance Leonard, who's the CEO of Genesis Innovation Group. And then Doctor Sean Churchill, who is a board member of the Genesis Innovation Group. Gentlemen, thanks for joining me today. It's nice to meet you.

Chance Leonard: Very nice to meet you as well.

Dr. Sean Churchill: Thanks for taking the time with us today.

So let's just start with an introduction. So maybe, Chance, start and talk to us about what is Genesis Innovation and your background a little bit so people get to know you a little.

CL: You bet. Well, thank you, Andy, for the opportunity to connect. My name is Chance Leonard, and as you mentioned, I currently serve as Chief Executive Officer of Genesis Innovation Group. We are a medical device development company, solely focused on med tech and in orthopedics, particularly. And we basically provide ...

Click the button below to download and read the complete transcript of our interview with Chance Leonard and R. Sean Churchill, MD, as they discuss the innovative SupraSpacer implant for the treatment of massive irreparable rotator cuff tears, conducted by Andy Knapik, SmartTRAK Sr. Analyst, Soft Tissue & Arthroscopic Technologies.

The Musculoskeletal New Ventures Conference meeting offers a glimpse into emerging and promising technologies that are shaping the US Spinal Hardware Market.

The Musculoskeletal New Ventures Conference (MNVC) took place on November 4-5, 2025, in Memphis, TN. This annual conference highlights new and emerging technologies focused on the orthopedics space, and this year alone had over 45 companies present. In this article, SmartTRAK highlights four spine-focused companies with novel technologies that will impact the broader US Spinal Hardware Market, which is projected to grow at a 5-year CAGR of +4.0% by 2029E, according to SmartTRAK estimates.  

The companies covered in this article are:

• ZygoFix
  Since its presentation at MNVC last year, ZygoFix has begun surgeries in the US and currently has five surgeons incorporating the zLock into their practices. The company plans to expand access in ... (read more)
  
  
• Nanohive
  Nanohive is focused on providing patient-specific interbody implants built on its proprietary soft titanium lattice platform, which has a lower modulus of elasticity than other titanium metals and is closer to ... (read more)
• Lenoss Medical
  Lenoss Medical offers a novel biological allograft implant, Osteopearl, for the VCF market, which eliminates the need for ... (read more)
  
  
• Synergy Spine Solutions
  Synergy Spine Solutions is currently participating in FDA clinical trials to bring its Synergy disc to the US market. This unique disc preserves motion and actively corrects alignment in the cervical spine due to ... (read more)

According to SmartTRAK Product Explorer, there are over 219 companies and approximately 1,150 products competing for market share in the US Spinal Hardware Market today. The MNVC meeting provided a glimpse into new and promising technologies for the US Spinal Hardware Market.

To learn more about MNVC 2025 and the companies presenting, click the button below to download the complete article by Erin Dorgan, SmartTRAK Sr Analyst, Spine & Bone Replacement.

This SmartTRAK interview features a panel of experts discussing the clinical shift in hip preservation toward pre-sutured, "off-the-shelf" allograft solutions.

In this interview, SmartTRAK hosts a distinguished panel featuring Andrew Jimenez, MD (Yale School of Medicine), Winston Gwathmey, MD (University of Virginia), and Kevin Whitten (chief commercial officer, AlloSource) to discuss the clinical realities of modern hip preservation. The conversation highlights the shift from time-consuming autograft preparations to innovative "off-the-shelf" allograft solutions. Specifically, the panel explores the operational and clinical advantages of AceConnex, a pre-prepared fascia lata allograft designed to reduce intra-op time and standardize outcomes in labral reconstruction procedures. Click on the following video to learn more (17:44 min). A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is David Shepard with SmartTRAK. It's my pleasure to be joined by Dr. Andrew Jimenez, the assistant professor of orthopedics and rehabilitation at Yale School of Medicine, and Dr. Winston Gwathmey, professor of orthopedic surgery at UVA. We're also joined by Kevin Whitten, chief commercial officer at AlloSource, and tonight we're going to be talking about AceConnex.

Thank you very much for joining us, gentlemen. And feel free to jump in at any time, so whoever wants to start with these questions, and again, feel free to interject and jump in. But the first thing I wanted to do is try to get a sense of exactly what type of clinical procedure we're doing here, or what's the issue that occurs with these patients, where AceConnex comes in and is an excellent solution for these patients.

Dr. Winston Gwathmey: I can get started. Hip arthroscopy is a procedure that addresses injuries of the hip that are soft tissue injuries, labral injuries, femoroacetabular impingement. And we've seen a proliferation of this procedure in the past 20 years or so. And with that, we're learning a lot more and more about how the hip functions. And what we're seeing in 2025 is that sometimes the labrum, the soft tissue gasket ring that fits around the hip joint, is not in a situation that can be repaired or salvaged. And so luckily, we've learned a procedure called a labral reconstruction in which we replace part or all of the labrum with the cadaver graft. And what that does is it provides a lot of labral functions and anatomy in a situation where the labrum is deficient or not repairable.

Dr. Andrew Jimenez: And just to piggyback off that, there's been a real evolution in terms of labral treatment and management. Early days of hip arthroscopy, starting off with just labral debridement and labral excision. As our techniques and our implants became better, we moved onto doing labral repair. And what we invariably came up with was ...

Want to learn more about the shift from time-consuming autograft preparations to innovative "off-the-shelf" allograft solutions? Click the button below to download and read the complete transcript of our roundtable discussion, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

The high costs and complexity involved in manual manufacturing hinder the commercial viability of regenerative cell therapies. Octane Biotherapeutics seeks to remove these barriers by integrating its automated "Cocoon" production system with the well-established Novocart 3D and Novocart Inject platforms. SmartTRAK interviews Dr. Robert Spiro, CEO of Octane Biotherapeutics, to explore the company's strategic acquisition of assets from Aesculap Biologics and TETEC AG, and their plan to make a significant entry into the US Cartilage Repair Market. 

Click on the following video to learn more (09:37 min). A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is David Shepard with SmartTRAK, and I'm here with Dr. Robert Spiro, the CEO of Octane Biotherapeutics. Thank you for taking the time, really appreciate it.

Robert Spiro: Good to see you, Dave. Thank you.

Yes, good to see you as well. Tell me a little bit about Octane and the acquisition of Novocart 3D and Novocart Inject by Octane.

RS: Sure. It's a journey. It really started about 2010, '11, when I first started with Aesculap Biologics in this space. And having been in the cartilage regenerative space through several companies, really knowing that the scale-up of any type of manual culture, cell culture system was a big challenge from a commercial standpoint. We have always been looking for ways to automate this process. We started some on our own, but I encountered this technology with Octane, which was back in 2011—started that collaboration to transfer our manual autologous chondrocyte culture process to an automated system. They had already really started on this Cocoon technology, but we started to marry it to the Novocart program that long ago.

The relationship was there, all along, with the divestiture away from B. Braun Aesculap as they restructured all of their portfolio. It was really a natural progression for Octane to step in and acquire the company, not only Aesculap Biologics, but our sister company in Germany, TETEC AG, that developed the same technology. Octane Biotherapeutics is fully global, both German as well as US. And so, the Cocoon technology is an important step for us to commercialize both Novocart 3D and Novocart Inject for a number of reasons, and anyone in the cell culture space understands that scale up, scale out of those kind of manual process is expensive. It's one of the things that drives the cost of these products so high. So, it's been a great collaboration, and the fact that they stepped in through the acquisition just made a lot of sense for everybody.

RS: The hallmark of this is why it's really ideal for autologous cells. It's this ...

Want to learn more about how integrating the automated "Cocoon" cell production system with Novocart 3D and Novocart Inject platforms will disrupt the complexity and costs of the US Cartilage Repair Market? Click the button below to download and read the complete transcript of our interview with Dr. Robert Spiro, CEO of Octane Biotherapeutics, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

Dr. Silverman discusses key takeaways from the AOFAS meeting, along with insights into his practice's shift to ASC settings and the major hurdles of fair reimbursement and staff recruitment.

Lance Silverman, MD, an orthopedic surgeon and foot and ankle specialist at Resurgens Orthopaedics in Roswell, GA, discusses trends and technologies in the Foot & Ankle Market in an interview with SmartTRAK.

Dr. Silverman discusses key takeaways from the recent American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting 2025, including the critical focus on avoiding revisions in total ankle replacements. He also addresses the role of technology, such as artificial intelligence (AI) surgical planning tools and the instrumentation and jigs used in foot and ankle procedures. Dr. Silverman provides insights into the current landscape of his practice, including his most common procedures, his shift to ambulatory surgery center (ASC) settings, and the benefits and biggest challenges he faces—such as securing fair reimbursement and the struggle to recruit and retain talented team members amid rising living costs and salary expectations.

To listen to the interview, click on the following video (17:46 min). A link to download a complete transcript of the interview is also provided below.

Interview

SmartTRAK: Hi, this is Natasha Weeks General Manager of Trauma and Extremities for SmartTRAK, and I'm here with Dr. Lance Silverman. We're going to take a deep dive into the foot and ankle segment. Dr. Silverman, thanks for being here and talking with me. And it was great to meet you at AOFAS in Savannah last month.

Dr. Lance Silverman: Nice to meet you there too, Natasha. It's a pleasure reconnecting.

Great. So reflecting on AOFAS and the meeting, for you, what was the most impactful message, whether that was clinical discussions you had, any specific posters or symposium talks or even products that you saw displayed? What did you believe coming off of that conference would really be most influential in the surgical management of foot and ankle?

LS: Well, there were a lot of conversations that people had both in lectures and outside of lectures on total ankle replacement. And total ankle replacement has been a growing increasingly performed procedure. And we have now started to see...

Want to learn more about the trends and technologies in the Foot & Ankle Market? Click the button below to download and read the complete transcript of our interview with Lance Silverman, MD, conducted by Natasha Weeks, Managing Editor/Sr. Analyst Trauma & Extremities.

Conmed’s Lisa Donnelly, VP of Marketing for US Orthopedics, and Jeff Ott, Director of R&D, discuss their BioBrace technology in an interview with SmartTRAK at OSET 2025 in Las Vegas. 

Conmed’s Lisa Donnelly, VP of Marketing for US Orthopedics, and Jeff Ott, Director of R&D, sat down with SmartTRAK at the Orthopaedic Summit (OSET) 2025 Annual Meeting in Las Vegas (September 18–25, 2025) to discuss BioBrace and how its bioinductive technology sets it apart from the competition.

To find out more about Conmed and BioBrace, click on the following video (16:30 min). A link to download a complete transcript of the interview is also provided below. 

Hey everybody, it's Andy Knapik with SmartTRAK, here at Ortho Summit in Las Vegas, and I'm happy to be here at the ConMed booth, and joined by a good friend of mine, Lisa Donnelly, who's VP of Marketing for US Ortho for ConMed, and then also Jeff Ott, who is a director of R&D. Why don't you just start by talking to us about how you started with the company? I'm just going to let you go with the intro part.

Jeff Ott: Yes, happy to do that. I joined a small company called Biorez about six or seven years ago as a small startup. We were focused on trying to find ways to help with tendon and ligament healing, and we developed a product called the BioBrace, which now is a part of ConMed.

So, when was that acquired? That was about a year…

Lisa Donnelly: August of 2022.

Okay. So a few years now. Wow. It's flown.

JO: Yes, time has flown by. So the BioBrace, which we developed, we designed a product that is a bioinductive scaffold with strength. What we did is we created a product that can both reinforce a tendon or ligament repair, and it also can ...

Want to learn more about the BioBrace technology? Click the button below to download and read the complete transcript of our exclusive interview with Conmed’s Lisa Donnelly, VP of Marketing for US Orthopedics, and Jeff Ott, Director of R&D, conducted by  Andy Knapik, SmartTRAK Sr. Analyst, Soft Tissue & Arthroscopic Technologies.